Compare Sempra Energy (SRE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sempra Energy vs Tango Therapeutics Inc. — how do they compare? Sempra Energy trades at $82.38 (market cap $53.61B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Sempra Energy is far larger — about 14.3× Tango Therapeutics Inc.'s market cap, and Sempra Energy pays a 3.21% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sempra Energy for 9 Days and Tango Therapeutics Inc. for 0 Days on average.
| SRE | TNGX | |
|---|---|---|
Market Cap | $53.61B | $3.74B |
Volume | 3,549,235 | 3,438,781 |
Sector | Utilities | Health |
52-Week High | $99.75 | $32.90 |
52-Week Low | $76.90 | $7.50 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $90.25B | $2.76B |
Dividend Yield | 3.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sempra Energy (SRE) trades at $82.37, up 0.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong Q2 2026 earnings that beat expectations, with a net income margin of 16.83% and robust cash flow from operations of $5.4 billion in 2026. Recent developments include a 20-year LNG supply agreement with Petrobras and the opening of SoCalGas' new headquarters, signaling growth initiatives.
The outlook for SRE is positive, supported by analyst consensus with an 80.77% buy rating and a price target of $97.25, implying significant upside. Key opportunities include EPS growth guidance of 7–9% and strategic investments in Texas and LNG. Risks involve high capital expenditures, regulatory exposure, and interest rate sensitivity. The stock's current valuation at a P/E of 23.88 requires continued execution to justify further gains.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sempra Energy
Sempra is an energy infrastructure company with regulated utility and energy network businesses. Its operations include electric and gas utilities as well as energy infrastructure in North America.
Read more on SRE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
